Central Sensitization Medication: Attorney Guide to High-Value Cases

James Wong — Founder & CEO, LienScripts | March 29, 2026 | 8 min read

Central sensitization — when the nervous system amplifies pain signals beyond the original injury — requires multi-drug treatment and produces pharmacy records documenting complex, chronic pain conditions with high settlement value. This attorney guide explains the clinical concept and its medication implications.

Central sensitization is a neurological phenomenon in which the central nervous system amplifies pain signals, causing patients to experience pain that is disproportionate to the tissue injury, pain in uninjured areas, and heightened sensitivity to stimuli that should not be painful. It is increasingly recognized as the mechanism underlying chronic pain conditions following personal injury, and the multi-drug medication regimen required to treat it produces pharmacy records that document one of the most complex and high-value injury presentations in PI litigation.

• Central sensitization occurs when repeated or intense pain signals from an injury alter the spinal cord and brain's pain processing, causing them to amplify all subsequent pain input (Woolf, Pain, 2011; Latremoliere & Woolf, J Pain, 2009)
• Treatment requires simultaneous medications targeting multiple mechanisms: gabapentinoids, SNRIs, low-dose naltrexone, NMDA antagonists, and topical agents — single-drug therapy is typically insufficient
• LienScripts covers all medications in the central sensitization regimen on pharmacy lien, and each case receives a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the multi-mechanism pharmacological approach
• According to James Wong, PharmD, founder of LienScripts, "Central sensitization cases generate the most complex pharmacy records we manage — five or six concurrent medications targeting different pain pathways, each one documenting that the nervous system itself has been permanently altered by the injury"
• The International Association for the Study of Pain (IASP) recognizes central sensitization as a distinct pathophysiological mechanism, giving it a clinical legitimacy that defense experts cannot easily dismiss

What Central Sensitization Means for PI Cases

Central sensitization transforms a localized injury into a widespread pain condition. A patient who was rear-ended and initially had neck pain may develop:

• Pain spreading to the shoulders, upper back, and arms (spatial summation)
• Increased pain sensitivity at the original injury site (hyperalgesia)
• Pain from light touch, clothing contact, or temperature changes (allodynia)
• Fatigue, sleep disruption, and cognitive difficulties ("brain fog")

These symptoms are not psychological or exaggerated — they reflect measurable changes in spinal cord dorsal horn neuron excitability and descending pain modulation pathways. Functional MRI studies have demonstrated altered brain connectivity patterns in patients with central sensitization (Nijs et al., J Orthop Sports Phys Ther, 2014).

[!KEY] Central sensitization is not a psychological condition or symptom exaggeration. It is a measurable neurological phenomenon — altered pain processing at the spinal cord and brain level — recognized by the IASP and documented through specific medication patterns that target the underlying neural mechanisms.

The Multi-Drug Treatment Approach

Central sensitization cannot be treated with a single medication because it involves multiple dysfunctional pathways simultaneously. The treatment regimen targets each pathway with a specific drug class:

1. Gabapentinoids — Reducing Neural Hyperexcitability

Gabapentin or pregabalin reduces the hyperexcitability of dorsal horn neurons by binding alpha-2-delta calcium channel subunits, decreasing excitatory neurotransmitter release.

• Gabapentin 1800-3600mg/day — titrated to high therapeutic doses
• Pregabalin 300-600mg/day — often preferred for its more predictable pharmacokinetics

High-dose gabapentinoid therapy documents that the neural hyperexcitability is severe — low doses were insufficient to dampen the amplified pain signals.

2. SNRIs — Enhancing Descending Inhibition

Duloxetine and venlafaxine strengthen the brain's descending pain inhibition pathways, which are impaired in central sensitization. These "top-down" pathways normally suppress excessive pain signals at the spinal cord level.

• Duloxetine 60-120mg/day — FDA-approved for chronic musculoskeletal pain
• Venlafaxine 150-225mg/day — norepinephrine reuptake at higher doses enhances pain inhibition

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When I see duloxetine 120mg — the maximum dose — alongside gabapentin 3600mg, the pharmacy record documents a nervous system that needs maximum pharmacological support at two different levels: reducing hyperexcitability and enhancing inhibition."

3. Low-Dose Naltrexone (LDN) — Glial Cell Modulation

Low-dose naltrexone (1.5-4.5mg daily, compounded) modulates microglial activation in the central nervous system. Microglia are immune cells in the brain and spinal cord that, when activated by chronic pain, release pro-inflammatory cytokines that perpetuate central sensitization (Younger et al., Pain Medicine, 2014).

LDN is a compounded medication — it cannot be obtained at standard retail pharmacies. Its presence in the pharmacy record documents that the treating provider has identified glial-mediated central sensitization and is treating it with a mechanism-specific agent.

4. NMDA Receptor Modulation

NMDA (N-methyl-D-aspartate) receptors in the spinal cord dorsal horn are key mediators of central sensitization. When chronically activated, they amplify pain signals through "wind-up" — progressively increasing neural responses to repeated stimuli.

• Memantine 5-20mg/day — NMDA antagonist used off-label for pain
• Topical ketamine (compounded cream) — NMDA antagonist applied locally

5. Topical Agents — Peripheral Desensitization

Topical agents reduce peripheral nerve input that drives central sensitization:

• Lidocaine 5% patches — local anesthetic reducing peripheral nerve firing
• Compound topical creams — combinations targeting multiple peripheral mechanisms
• Capsaicin (Qutenza) 8% patch — depletes substance P from peripheral nerves

[!TIP] Count the number of concurrent medications in a central sensitization case. Each drug class targets a different pain mechanism, and the total count directly reflects the number of dysfunctional pathways the treating provider has identified. Five or six concurrent medications document five or six separate pain mechanism abnormalities — an injury profile that no defense expert can characterize as "minor."

Settlement Value Implications

Why Central Sensitization Cases Are High-Value

1. Multi-drug regimens — five or more concurrent medications generate extensive monthly pharmacy records
2. Treatment duration — central sensitization is typically chronic or permanent, requiring indefinite treatment
3. Functional impairment — allodynia, hyperalgesia, and fatigue significantly impact daily life and employment
4. Treatment resistance — central sensitization responds partially to each medication but rarely resolves completely
5. Future medical costs — the multi-drug regimen projected over decades represents substantial lifetime pharmacy costs

The Pharmacy Record as Objective Evidence

Subjective pain complaints are easy for defense to challenge. The pharmacy record is objective. A patient filling five concurrent medications monthly for 18 months has 90 documented pharmacy transactions — each one a prescriber-ordered, pharmacist-verified record of ongoing pain management.

[!KEY] Central sensitization cases produce the highest medication counts and longest treatment durations in PI pharmacy. The resulting pharmacy record — five or six drugs across 12-36+ months — generates a volume of objective medical documentation that overwhelms defense arguments of minor injury or symptom exaggeration.

Identifying Central Sensitization in Your Cases

Clinical Red Flags

• Pain spreading beyond the original injury area
• Increasing pain sensitivity over time (not improving as expected)
• Pain from non-painful stimuli (light touch, clothing, temperature)
• Poor response to standard pain medications at appropriate doses
• Associated fatigue, sleep disturbance, and cognitive difficulties

Pharmacy Record Red Flags

• Multiple pain medications from different drug classes added over time
• Gabapentinoid dose escalation to maximum ranges
• Addition of compounded medications (LDN, topical compounds)
• SNRI prescribed at maximum doses alongside gabapentinoids
• Treatment duration extending well beyond expected healing timelines

Defense Arguments and Rebuttals

"Central Sensitization Is Not a Real Diagnosis"

The IASP — the world's leading pain research organization — recognizes central sensitization as a distinct pathophysiological mechanism. Functional MRI studies have demonstrated measurable brain connectivity changes. The medication pattern itself documents the treating provider's diagnosis.

"The Patient Is Exaggerating Pain"

The multi-drug regimen prescribed by the treating provider — not requested by the patient — documents the provider's clinical assessment of pain severity. Providers do not prescribe five concurrent pain medications for exaggerated symptoms.

"These Medications Are Excessive"

Each medication targets a different mechanism. Gabapentinoids address hyperexcitability, SNRIs enhance inhibition, LDN modulates glial cells, and topicals reduce peripheral input. The multi-drug approach follows pain medicine guidelines for central sensitization management.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the mechanism-specific rationale for each medication in the regimen.

Frequently Asked Questions

For lien-based coverage of all central sensitization medications, LienScripts provides pharmacy services for personal injury patients with no upfront cost.

Related Resources

• CRPS/RSD Medication Management on Lien
• Peripheral Neuropathy Medication in PI Settlement
• Polypharmacy in Complex Injury Settlement Value
• Gabapentin for Whiplash Nerve Pain
• Duloxetine for Chronic Pain After an Accident